Companies /Healthcare
Novavax Inc
NASDAQ: NVAX Biotechnology
$7.89
▼ $0.08 (−0.94%) today
Markets open · 10:38am ET

Novavax (NVAX) Q3 2026 Earnings

Reported Nov 5, 2026, 8:00am ET
$-0.19
Beat +45.09%
EPS · est. $-0.35 GAAP

Quarter includes $11 million in non-cash deferred royalty recognition related to prior Nuvaxovid sales by SK bioscience to the South Korean government; no non-GAAP EPS disclosed.

$68.3M
Beat +35.45%
Revenue · est. $50.4M
4 quarters
Consecutive EPS beats

How Did NVAX Stock React to Q3 2026 Earnings?

% change · around the report
−15%−10%−5%0Nov 5Nov 6report 8:00am ETearnings−3.8%−5.7%
−15%−10%−5%0Nov 5Nov 6earnings−3.8%−5.7%
NVAX −5.7%S&P 500 −3.8%
−15%−10%−5%0Nov 5Nov 6report 8:00am ETearnings−4.0%−5.7%
−15%−10%−5%0Nov 5Nov 6earnings−4.0%−5.7%
NVAX −5.7%NASDAQ −4.0%
−14%−7%0+7%Nov 4Nov 12report 8:00am ETearnings−1.1%−15.5%
−14%−7%0+7%Nov 4Nov 12earnings−1.1%−15.5%
NVAX −15.5%S&P 500 −1.1%
−14%−7%0+7%Nov 4Nov 12report 8:00am ETearnings+0.8%−15.5%
−14%−7%0+7%Nov 4Nov 12earnings+0.8%−15.5%
NVAX −15.5%NASDAQ +0.8%
−8.17%
Day of report
+10.22%
Next session
−10.43%
One week

Did NVAX Beat Earnings? Q3 2026 Results

Yes. Novavax reported Q3 2026 earnings of $-0.19 a share on Nov 5, 2026, beating the $-0.35 consensus estimate by 45.1%. Revenue was $68.3M against a $50.4M estimate.

Novavax delivered a decisive beat in the third quarter of 2026, posting GAAP EPS of negative $0.19 against a consensus estimate of negative $0.35, a 45.09% positive surprise, while revenue of $68.30 million cleared the $50.42 million consensus by 35.45%, even as the top line slipped 3.0% year over year. The quarter's results, which included $11.00 million in non-cash deferred royalty recognition tied to SK bioscience's prior Nuvaxovid sales to the South Korean government, reflected Novavax's continuing pivot toward a partnership- and royalty-driven model; product sales surged 91% to roughly $26.00 million on Nuvaxovid supply to Sanofi, partly offsetting a sharp drop in R&D reimbursement revenue as Novavax winds down its clinical support for Sanofi's postmarketing commitments. Sanofi's October initiation of a Phase 3 European trial for a combination influenza-COVID-19 vaccine, which triggered a $125.00 million milestone for Novavax, prompted management to raise full-year 2026 Non-GAAP Adjusted Total Revenue guidance to $385.00 million to $415.00 million, up from a prior range of $235.00 million to $275.00 million.

Key Takeaways
  • Product sales up 91% on supply sales of Nuvaxovid to Sanofi and Matrix-M to license partners
  • Licensing revenue down 25%, driven by a $42 million year-over-year reduction in R&D reimbursement revenue
  • $11 million non-cash deferred royalty recognition related to SK bioscience prior Nuvaxovid sales
  • R&D expenses down 47% on near completion of Sanofi clinical support, reduced strain change support and cost reduction
  • SG&A down 25% on transition of commercial activities to Sanofi and elimination of commercial infrastructure
  • No repeat of the prior-year $97.0 million impairment and $28.7 million loss on debt extinguishment

“This quarter, we continued to execute across all three pillars of our strategy. Our partner Sanofi initiated their Phase 3 influenza-COVID-19 combination vaccine trial vaccine trial in Europe, triggering a $125 million milestone payment.”

Novavax CEO, on the earnings call

What Is Novavax's Outlook?

Novavax raised its full-year 2026 Non-GAAP Adjusted Total Revenue framework to $385–$415 million, from $235–$275 million as of August 6, 2026. The framework's components are: - Nuvaxovid Product Sales of $40–$50 million, expected to be excluded from the 2027 framework. - Adjusted Supply Sales of $50–$60 million. - The $125 million Sanofi CIC milestone. - Adjusted Licensing, Royalties and Other Revenue of $170–$180 million, made up of: - $60 million in R&D reimbursement, with $5 million expected in 2027. - $70–$80 million of other partner revenue, including the $30 million Pfizer upfront payment. - $40 million of amortization of the Sanofi upfront and database lock payments. Full-year 2026 expense guidance: - Combined R&D and SG&A Expenses of $375–$395 million, versus $370–$410 million previously. - Non-GAAP Combined R&D and SG&A Expenses of $315–$335 million, versus $310–$340 million previously. Sanofi supply sales, royalties and future milestones are excluded from guidance. Expected Sanofi milestones include: - $75 million on completion of the technology transfer, expected mid-2027. - $225 million on the first U.S. commercial sale of a CIC vaccine. Sanofi intends to start a U.S. Phase 3 CIC trial in 2027.

NVAX YoY Financials

Q3 2026 vs Q3 2025 · SEC filings Q3 2025 Q3 2026
$-30,000,000$0$30.0M$60.0M$70.4M$68.3MRevenue$-17,146,851$-31,281,000Operating Income$-17,005,962$-31,376,000Net Income
$-30,000,000$0$30.0M$60.0MRevenueOperating IncomeNet Income
NVAX income statement, Q3 2026 versus Q3 2025
Metric Q3 2026 Q3 2025 Year over year
Revenue $68.3M $70.4M −3.1%
Operating Income −$31.3M −$17.1M +82.4%
Net Income −$31.4M −$17.0M +84.5%

NVAX Revenue by Segment

Nuvaxovid Sales
Sanofi Licensing$19.0M−61.0%
Licensing, Royalties and Other Revenue
Supply Sales$25.7M+91.0%
Takeda
Other Partners Licensing$11.0M+100.0%
Takeda Licensing$7.0M+14.0%
Other Partners

Figures from SEC filings and company reports. Not investment advice.